021-51111890
购物车（）
sales@molnova.cn
ASP3026
CAS No. 1097917-15-1
ASP3026 ( ASP 3026;ASP-3026 )
产品货号. M10377 CAS No. 1097917-15-1
ASP3026 is a potent small molecule ALK inhibitor with IC50 of 3.5, 10, 5.4 and 6.8 nM for wt ALK, ALK F1174L, ALK R1275Q and NPM1-ALK, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥284 | 有现货 |
|
| 5MG | ￥437 | 有现货 |
|
| 10MG | ￥640 | 有现货 |
|
| 25MG | ￥1085 | 有现货 |
|
| 50MG | ￥1604 | 有现货 |
|
| 100MG | ￥2657 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ASP3026
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ASP3026 is a potent small molecule ALK inhibitor with IC50 of 3.5, 10, 5.4 and 6.8 nM for wt ALK, ALK F1174L, ALK R1275Q and NPM1-ALK, respectively.
-
产品描述ASP3026 is a potent small molecule ALK inhibitor with IC50 of 3.5, 10, 5.4 and 6.8 nM for wt ALK, ALK F1174L, ALK R1275Q and NPM1-ALK, respectively; also potently inhibits Ack, EGFR L858R, FRK and LTK with IC50 of 5-85 nM, inhibits the growth of NCI-H2228 cells with IC50 of 64.8 nM; enhances the antitumor activities of paclitaxel and pemetrexed without affecting body weight in mice model.Blood Cancer Phase 1 Discontinued
-
同义词ASP 3026;ASP-3026
-
通路Angiogenesis
-
靶点ALK
-
受体ALK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1097917-15-1
-
分子量580.70
-
分子式C29H40N8O3S
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESO=S(C1=CC=CC=C1NC2=NC=NC(NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3OC)=N2)(C(C)C)=O
-
化学全称1,3,5-Triazine-2,4-diamine, N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Mori M, et al. Mol Cancer Ther. 2014 Feb;13(2):329-40.
2. George SK, et al. Oncotarget. 2014 Jul 30;5(14):5750-63.
3. Mologni L, et al. Oncotarget. 2015 Mar 20;6(8):5720-34.
4. Iikubo K, et al. Chem Pharm Bull (Tokyo). 2018;66(3):251-262.
2. George SK, et al. Oncotarget. 2014 Jul 30;5(14):5750-63.
3. Mologni L, et al. Oncotarget. 2015 Mar 20;6(8):5720-34.
4. Iikubo K, et al. Chem Pharm Bull (Tokyo). 2018;66(3):251-262.
产品手册
关联产品
-
JH-VIII-157-02
JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM.
-
AZD3463
AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency.
-
Alofanib
Alofanib is a selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect on FGF2-induced phosphorylation of FRS2a in KATO III cells (IC50 <10 nM).
